Robotic Surgery for Biliary Tract Cancer

被引:13
|
作者
Kone, Lyonell B. [1 ]
Bystrom, Philip V. [1 ]
Maker, Ajay V. [2 ]
机构
[1] Univ Illinois, Metropolitan Grp Hosp, Chicago, IL 60607 USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
关键词
cholangiocarcinoma; gallbladder cancer; robotic surgery; biliary tract cancer; klatskin tumor; minimally invasive surgery; HILAR CHOLANGIOCARCINOMA; GALLBLADDER CANCER; RADICAL RESECTION; OUTCOMES;
D O I
10.3390/cancers14041046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Complete surgical resection of biliary tract cancer provides the best chance at long-term survival. These surgeries are complex and can be associated with high morbidity and prolonged recovery. Minimally invasive approaches have been shown to improve some of these outcomes in other cancers. However, there is a paucity of data in biliary cancer, and even less is known about the outcomes of surgery utilizing a robotic platform. The present review reports the pooled outcomes of robotic surgery for 259 patients with biliary tract cancer. These outcomes are often equivalent to or improved compared to contemporary data on open surgery. The published data lack prospective or randomized studies. Thus, to evaluate any of the potential benefits of robotic surgery for biliary tract cancer, higher-quality studies are needed. Biliary tract cancer consists of cholangiocarcinoma (CC) and gallbladder cancer (GBC). When resectable, surgery provides the best chance at long-term survival. Unfortunately, surgery for these tumors is associated with long operative times, high morbidities, and prolonged hospital stays. Minimally invasive surgery has been shown to impact selected outcomes, including length of stay, in other diseases, and robotic surgery may offer additional advantages compared to laparoscopic surgery in treating bile duct cancers. This is a systematic review of robotic surgery for biliary tract cancer. Predetermined selection criteria were used to appraise the literature. The PRISMA guidelines were followed. In total, 20 unique articles with a total of 259 patients with biliary tract cancer undergoing robotic surgery met the inclusion criteria. For CC and GBC, respectively, the weighted average operative time was 401 and 277 min, the estimated blood loss was 348 and 260 mL, the conversion rate to open was 7 and 3.5%, the all-cause morbidity was 52 and 9.7%, the major morbidity was 12 and 4.4%, the perioperative mortality was 1.4 and 0%, the length of stay was 15 and 4.8 days, the positive margin rate was 27 and 9%, and the number of lymph nodes retrieved was 4.2 and 8. Robotic surgery for biliary tract cancer appears non-inferior to open surgery when compared to the published contemporary data. However, the current literature on the topic is of low quality, and future prospective/randomized studies are needed.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Robotic Surgery of the Liver and Biliary Tract
    Guerra, Francesco
    Di Marino, Michele
    Coratti, Andrea
    JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES, 2019, 29 (02): : 141 - 146
  • [2] Robotic Biliary Surgery
    Chang, Karen
    Gokcal, Fahri
    Kudsi, Omar Yusef
    SURGICAL CLINICS OF NORTH AMERICA, 2020, 100 (02) : 283 - +
  • [3] Surgery for Recurrent Biliary Tract Cancer A Single-center Experience With 74 Consecutive Resections
    Takahashi, Yu
    Ebata, Tomoki
    Yokoyama, Yukihiro
    Igami, Tsuyoshi
    Sugawara, Gen
    Mizuno, Takashi
    Nimura, Yuji
    Nagino, Masato
    ANNALS OF SURGERY, 2015, 262 (01) : 121 - 129
  • [4] Essential updates to the surgical treatment of biliary tract cancer
    Matsukuma, Satoshi
    Tokumitsu, Yukio
    Shindo, Yoshitaro
    Matsui, Hiroto
    Nagano, Hiroaki
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2019, 3 (04): : 378 - 389
  • [5] Molecular characteristics of biliary tract cancer
    Sohal, Davendra P. S.
    Shrotriya, Shiva
    Abazeed, Mohamed
    Cruise, Michael
    Khorana, Alok
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 107 : 111 - 118
  • [6] Surgical treatment of malignant biliary tract diseases
    Schmelzle, M.
    Schoening, W.
    Pratschke, J.
    CHIRURG, 2020, 91 (01): : 3 - 10
  • [7] Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials
    Nara, Satoshi
    Esaki, Minoru
    Ban, Daisuke
    Takamoto, Takeshi
    Shimada, Kazuaki
    Ioka, Tatsuya
    Okusaka, Takuji
    Ishii, Hiroshi
    Furuse, Junji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1353 - 1363
  • [8] Biliary tract cancer: on the way to a personalized therapy
    Sinn, Marianne
    Wege, Henning
    Stein, Alexander
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2020, 145 (07) : 442 - 446
  • [9] How I treat biliary tract cancer
    Lamarca, A.
    Edeline, J.
    Goyal, L.
    ESMO OPEN, 2022, 7 (01)
  • [10] Microbiome and Biliary Tract Cancer
    Park, Jin-Seok
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (01) : 1 - 5